<DOC>
	<DOC>NCT00859105</DOC>
	<brief_summary>Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Bio-equivalence Study</brief_summary>
	<brief_title>A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Patients must have 4 to 8 clinically diagnosed, nonhyperkeratotic, nonhypertrophic AK lesions within a 25 cm2 contiguous treatment area on either the face or balding scalp Women either must be 1 year postmenopausal, surgically sterile, or agree to use a medically accepted form or birth control Free of any systemic or dermatological disorder Any skin type or race, providing the skin pigmentation will allow discernment of erythema Basal cell or squamous cell carcinoma, or other possible confounding skin conditions (on face and scalp) History of cutaneous hyperreactivity or facial irritation to topical products Engaging in activities involving excessive or prolonged exposure to sunlight Receiving systemic cancer chemotherapy, psoralen plus UVA therapy, UVB therapy, laser abrasion, dermabrasion, glycolic acids, or chemical peels 6 months prior to study entry Currently using or have used systemic steroids 2 months prior to study Currently using or have used on the treatment area overthecounter retinol products, corticosteroids, cryosurgery, curettage, 5fluorouracil, or other topical actinic keratosis treatments 28 days prior to randomization Pregnant or nursing mothers History of allergy or sensitivity to imiquimod or related compounds or other components of the formulation Taking immunosuppressant medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>